Moreadith Randall 4

What Happened

• Moreadith Randall, Chief Scientific Officer of Serina Therapeutics (SER), exercised stock options and sold the resulting shares on January 28, 2026. She acquired 6,500 shares by exercising options at $0.06/share (cost $390) and sold 6,500 shares in the open market at a weighted average price of $3.57/share for proceeds reported as $23,186. Net proceeds after the exercise cost were about $22,796. The filing also shows an additional derivative conversion entry at $0.00; the filing does not attach further detail beyond the footnotes.

Key Details

• Transaction date: 2026-01-28 (reported in Form 4 filed 2026-01-29 — appears timely)
• Exercise: 6,500 shares @ $0.06 (total cost $390)
• Sale: 6,500 shares @ weighted avg $3.57 (total proceeds $23,186); prices in the sale ranged from $3.59 to $3.55 per the footnote
• Shares owned after transaction: Not disclosed in this filing
• Footnotes: F1 notes the sale price is a weighted average (sales ranged $3.59–$3.55) and the reporter will provide per‑trade prices on request; F2 states the stock options were fully vested
• Filing timeliness: Reported the next day (no late filing indicated)

Context

• This was an options exercise followed by an immediate open‑market sale of the exercised shares (common way for insiders to monetize vested options). The filing shows the exercise and sale occurred the same day, effectively converting option value to cash. No 10b5‑1 plan, gift, or tax‑withholding details are included in this filing.